New, Previously Unknown, Uses of Optical Coherence Tomography Angiography (OCTA) (OCTA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03068702|
Recruitment Status : Completed
First Posted : March 3, 2017
Last Update Posted : March 3, 2017
|Condition or disease||Intervention/treatment|
|Sickle Cell Retinopathy||Device: Optical Coherence Tomography Angiography|
|Study Type :||Observational|
|Actual Enrollment :||2 participants|
|Official Title:||New, Previously Unknown, Uses of Optical Coherence Tomography Angiography (OCTA): Sickle Cell Maculopathy|
|Actual Study Start Date :||August 21, 2016|
|Actual Primary Completion Date :||January 12, 2017|
|Actual Study Completion Date :||February 21, 2017|
African Canadians with sickle cell disease maculopathy diagnosed by OCTA.
Device: Optical Coherence Tomography Angiography
- vascular changes seen in the macular vasculature of people with sickle cell disease/ trait as compared to macular vasculature of normal macula. [ Time Frame: through study completion, an average of one year ]in this angiography the delicate vasculature of the macula can be clearly visualized and documented.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03068702
|Principal Investigator:||shawkat s Michel, MD, FRCS Ed||Dr. S.S. Michel Clinic, 214 MHC, 156 street and 87 Ave, Edmonton, AB, Canada|